Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes
Chadi M. Saad-Roy, Sinead E. Morris, View ORCID ProfileC. Jessica E. Metcalf, Michael J. Mina, Rachel E. Baker, Jeremy Farrar, Edward C. Holmes, Oliver G. Pybus, Andrea L. Graham, Simon A. Levin, Bryan T. Grenfell, Caroline E. Wagner
doi: https://doi.org/10.1101/2021.02.01.21250944
Chadi M. Saad-Roy
1Lewis-Sigler Institute for Integrative Genomics, Princeton NJ 08540, USA
Sinead E. Morris
5Department of Pathology and Cell Biology, Columbia University Medical Center, New York NY 10032, USA
C. Jessica E. Metcalf
2Department of Ecology and Evolutionary Biology, Princeton NJ 08540, USA
3Princeton School of Public and International Affairs, Princeton NJ 08540, USA
Michael J. Mina
6Departments of Epidemiology and Immunology and Infectious Diseases, Harvard School of Public Health, Boston MA 02115, USA
Rachel E. Baker
2Department of Ecology and Evolutionary Biology, Princeton NJ 08540, USA
4Princeton Environmental Institute, Princeton University, Princeton NJ 08540, USA
Jeremy Farrar
7The Wellcome Trust, London, UK
Edward C. Holmes
8Marie Bashir Institute for Infectious Diseases and Biosecurity, School of Life and Environmental Sciences and School of Medical Sciences, The University of Sydney, Sydney, NSW, Australia
Oliver G. Pybus
9Department of Zoology, University of Oxford, Oxford, UK
Andrea L. Graham
2Department of Ecology and Evolutionary Biology, Princeton NJ 08540, USA
Simon A. Levin
2Department of Ecology and Evolutionary Biology, Princeton NJ 08540, USA
Bryan T. Grenfell
2Department of Ecology and Evolutionary Biology, Princeton NJ 08540, USA
3Princeton School of Public and International Affairs, Princeton NJ 08540, USA
10Fogarty International Center, National Institutes of Health, Bethesda MD 20892, USA
Caroline E. Wagner
11Department of Bioengineering, McGill University, Montreal QC H3A 0C3, Canada
Data Availability
The manuscript does not include new data
Posted February 03, 2021.
Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes
Chadi M. Saad-Roy, Sinead E. Morris, C. Jessica E. Metcalf, Michael J. Mina, Rachel E. Baker, Jeremy Farrar, Edward C. Holmes, Oliver G. Pybus, Andrea L. Graham, Simon A. Levin, Bryan T. Grenfell, Caroline E. Wagner
medRxiv 2021.02.01.21250944; doi: https://doi.org/10.1101/2021.02.01.21250944
Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes
Chadi M. Saad-Roy, Sinead E. Morris, C. Jessica E. Metcalf, Michael J. Mina, Rachel E. Baker, Jeremy Farrar, Edward C. Holmes, Oliver G. Pybus, Andrea L. Graham, Simon A. Levin, Bryan T. Grenfell, Caroline E. Wagner
medRxiv 2021.02.01.21250944; doi: https://doi.org/10.1101/2021.02.01.21250944
Subject Area
Subject Areas
- Addiction Medicine (383)
- Allergy and Immunology (699)
- Anesthesia (192)
- Cardiovascular Medicine (2848)
- Dermatology (244)
- Emergency Medicine (429)
- Epidemiology (12559)
- Forensic Medicine (10)
- Gastroenterology (806)
- Genetic and Genomic Medicine (4433)
- Geriatric Medicine (401)
- Health Economics (716)
- Health Informatics (2850)
- Health Policy (1048)
- Hematology (375)
- HIV/AIDS (893)
- Medical Education (413)
- Medical Ethics (114)
- Nephrology (462)
- Neurology (4192)
- Nursing (222)
- Nutrition (617)
- Oncology (2204)
- Ophthalmology (624)
- Orthopedics (254)
- Otolaryngology (318)
- Pain Medicine (268)
- Palliative Medicine (82)
- Pathology (486)
- Pediatrics (1171)
- Primary Care Research (483)
- Public and Global Health (6779)
- Radiology and Imaging (1490)
- Respiratory Medicine (900)
- Rheumatology (430)
- Sports Medicine (369)
- Surgery (473)
- Toxicology (57)
- Transplantation (201)
- Urology (174)